RESUMEN
Background: Intraoperative blood salvage autotransfusion(IBSA) has been widely used in a variety of surgeries, but the use of IBSA in hepatocellular carcinoma (HCC) patients undergoing liver transplantation (LT) is controversial. Numerous studies have reported that IBSA used during LT for HCC is not associated with adverse oncologic outcomes. This systematic review and meta-analysis aims to estimate the clinical prognosis of IBSA for patients with H+CC undergoing LT. Methods: MEDLINE, Embase, Web of Science, and Cochrane Library were searched for articles describing IBSA in HCC patients undergoing LT from the date of inception until May 1, 2022, and a meta-analysis was performed. Study heterogeneity was assessed by I2 test. Publication bias was evaluated by funnel plots, Egger's and Begg's test. Results: 12 studies enrolling a total of 2253 cases (1374 IBSA and 879 non-IBSA cases) are included in this meta-analysis. The recurrence rate(RR) at 5-year(OR=0.75; 95%CI, 0.59-0.95; P=0.02) and 7-year(OR=0.65; 95%CI, 0.55-0.97; P=0.03) in the IBSA group is slightly lower than non-IBSA group. There are no significant differences in the 1-year RR(OR=0.77; 95% CI, 0.56-1.06; P=0.10), 3-years RR (OR=0.79; 95% CI, 0.62-1.01; P=0.06),1-year overall survival outcome(OS) (OR=0.90; 95% CI, 0.63-1.28; P=0.57), 3-year OS(OR=1.16; 95% CI, 0.83-1.62; P=0.38), 5-year OS(OR=1.04; 95% CI, 0.76-1.40; P=0.82),1-year disease-free survival rate(DFS) (OR=0.80; 95%CI, 0.49-1.30; P=0.36), 3-year DFS(OR=0.99; 95%CI, 0.64-1.55; P=0.98), and 5-year DFS(OR=0.88; 95%CI, 0.60-1.28; P=0.50). Subgroup analysis shows a difference in the use of leukocyte depletion filters group of 5-year RR(OR=0.73; 95%CI, 0.55-0.96; P=0.03). No significant differences are found in other subgroups. Conclusions: IBSA provides comparable survival outcomes relative to allogeneic blood transfusion and does not increase the tumor recurrence for HCC patients after LT. Systematic review registration: https://www.crd.york.ac.uk/prospero/, identifier CRD42022295479.
RESUMEN
BACKGROUND: Previous results from studies on the relationship between coffee/caffeine consumption and risk of urinary incontinence (UI) are inconclusive. We aim to assess this association using a meta-analysis of observational studies. METHODS: Pertinent studies were identified by searching electronic database (Embase, PubMed and Web of Science) and carefully reviewing the reference lists of pertinent articles until July 2015. Random-effects models were used to derive the summary ORs and corresponding 95 % CIs. RESULTS: Seven studies (one case-control, two cohort and four cross-sectional) were included in our meta-analysis. The summary ORs for any versus non-consumption were 0.75 (95 % CI 0.54-1.04) for coffee and 1.29 (95 % CI 0.94-1.76) for caffeine consumption. Compared with individuals who never drink coffee, the pooled OR of UI was 0.99 (95 % CI 0.83-1.18) for regular coffee/caffeine drinkers. Coffee/caffeine consumption was not associated with moderate to severe UI (OR 1.18, 95 % CI 0.88-1.58). In stratified analyses by gender, no significant association was found between UI risk and coffee/caffeine consumption in both men (OR 0.99, 95 % CI 0.42-2.32) and women (OR 0.92, 95 % CI 0.80-1.06). By subtype, the pooled ORs were 1.01 (95 % CI 0.86-1.19) for stress UI, 0.99 (95 % CI 0.84-1.16) for urge UI and 0.93 (95 % CI 0.79-1.10) for mixed UI. CONCLUSIONS: This meta-analysis found no evidence for an association between coffee/caffeine consumption and the risk of UI.